A Phase Ⅱ Study to Evaluate the Safety and Immunogenicity of COVID-19 Vaccine

Conditions: SARS-CoV-2 Infection Interventions: Biological: COVID-19 mRNA Vaccine (ZSVG-02-O); Biological: COVID-19 mRNA Vaccine (ZSVG-02-O); Biological: COVID-19 Vaccine (Vero Cell) ,Inactivated Sponsors: CNBG-Virogin Biotech (Shanghai) Ltd. Recruiting

https://clinicaltrials.gov/study/NCT06113731

Source: ClinicalTrials.gov - November 2, 2023 Category: Research Source Type: clinical trials